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Abstract
Background: We performed this study to develop a new scoring system to stratify different levels
of risk in patients admitted to hospital with a diagnosis of unstable angina (UA), which is a complex
syndrome that encompasses different outcomes. Many prognostic variables have been described
but few efforts have been made to group them in order to enhance their individual predictive
power.
Methods: In a first phase, 473 patients were prospectively analyzed to determine which factors
were significantly associated with the in-hospital occurrence of refractory ischemia, acute
myocardial infarction (AMI) or death. A risk score ranging from 0 to 10 points was developed using
a multivariate analysis. In a second phase, such score was validated in a new sample of 242 patients
and it was finally applied to the entire population (n = 715).
Results: ST-segment deviation on the electrocardiogram, age ≥ 70 years, previous bypass surgery
and troponin T ≥ 0.1 ng/mL were found as independent prognostic variables. A clear distinction
was shown among categories of low, intermediate and high risk, defined according to the risk score.
The incidence of the triple end-point was 6 %, 19.2 % and 44.7 % respectively, and the figures for
AMI or death were 2 %, 11.4 % and 27.6 % respectively (p < 0.001).
Conclusions: This new scoring system is simple and easy to achieve. It allows a very good
stratification of risk in patients having a clinical diagnosis of UA. They may be divided in three
categories, which could be of help in the decision-making process.
Background
Unstable angina (UA) is a complex syndrome with many
different clinical presentations which share a common
pathophysiologic background [1,2]. Plaque rupture or
erosion, platelet activation, coronary spasm, thrombosis
and oxygen supply/demand imbalance are well known
mechanisms responsible for the diverse manifestations of
the disease [3]. Prognosis of patients admitted to coronary
care units with the clinical diagnosis of UA has strikingly
improved in the last decades, but the spectrum of out-
comes among different patients continues to be broad.
There is general agreement that risk stratification is man-
datory in this population and many markers of increased
risk of serious events have been described over time [4–
10].
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Refractory angina seems to be the strongest predictor of
acute myocardial infarction or death, but this marker is
not available at admission, preventing an early assessment
of risk [11]. Although several clinical, electrocardio-
graphic and biochemical factors have been clearly shown
to increase risk in UA, few attempts have been made to
combine them in order to improve their individual prog-
nostic accuracy [12,13].
We decided to test the prognostic value of a combination
of such markers resulting in a prospectively designed score
that could be capable of making a clear distinction of dif-
ferent clinical outcomes applied to patients coming to
hospital with an UA admission diagnosis. With that pur-
pose we chose the most widely available prognostic varia-
bles that, in our model, provided the best independent
information for the occurrence of major in-hospital
events. The new score was applied in another cohort of
patients consecutively admitted to several coronary care
units who were not enrolled in trials of therapeutic
interventions.
Methods
Study population
Between January 2000 and June 2001, patients admitted
to coronary care units with a clinical diagnosis of UA were
included in the study if they fulfilled the following crite-
ria: a) class III-IV angina beginning in the last 2 months
(new onset angina) or previous stable angina increasing
in frequency, duration of pain or occurring at lower
threshold (progressive angina); b) last episode of pain at
rest or at minimal exertion occurring in the previous 48
hours and lasting more than 10 minutes.
Exclusion criteria were: a) Braunwald class A (secondary
angina) or class C (postinfarction angina); b) acute myo-
cardial infarction (AMI) defined as the elevation of creat-
ine kinase at least twice the upper limit of normal values
and a creatine kinase-MB fraction higher than 5 % of the
total creatine kinase value within the first 8 hours from
the onset of the last episode of ischemic pain; c) left bun-
dle branch block.
Electrocardiographic (ECG) changes were evaluated using
the admission ECG recordings. ST segment deviation was
defined as 1 mm or more elevation or depression of the ST
segment measured at 0.08 sec from the J point in at least
2 contiguous leads.
Ten coronary care units participated in the study. Seven of
them had catheterization facilities on site. The protocol
was approved by the local ethics committees at each par-
ticipating center.
Biochemical analysis
Cardiac-specific troponin T was measured using a rapid
bedside assay where blood reacts with monoclonal anti-
bodies, with a minimal detection level of 0.1 ng/mL [14].
Determination of C-reactive protein: blood samples were
stored in evacuated tubes (BD Biosciences) at -80°C to be
processed by immunoturbidimetric assay (Tina-quant
CRP; Roche) in a central laboratory where all the samples
were sent. The C-reactive protein detection range corre-
sponds to values of 0.1 to 48 mg/dL, with an interassay
variation coefficient of <5%. Measurements were cali-
brated against CRM 470 standards.
Blood samples for both determinations were taken at least
eight hours from the onset of the last episode of ischemic
pain.
Clinical end-points
The double end-point consisted of in-hospital death or
AMI, defined as the presence of two of the following three
criteria: prolonged ischemic pain (>20 minutes), new Q
waves development in 2 or more contiguous leads, and
creatine kinase doubling the upper normal value with MB
fraction >5 % of total creatine kinase value. The triple end-
point included in-hospital death, AMI or refractory
angina, which was defined as one or more symptomatic
ischemic episodes with ST-T changes on the ECG or
hemodynamic instability, lasting at least 10 minutes
being the patient treated with aspirin, nitrates, beta block-
ers or calcium antagonists and heparin (either unfraction-
ated or low-molecular weight) in adequate doses, unless
contraindicated.
Data management and statistical analysis
Continuous variables are presented as mean ± SD. In
order to develop a risk score, all demographic, clinical,
ECG and biochemical variables routinely collected at
admission to coronary care units were entered into an uni-
variate analysis and related to the triple end-point. Uni-
variate comparisons were made using the chi-square test
for categorical variables and the t-test for continuous ones.
Every variable resulting in a p value <0.10 for the triple
end-point was entered into a multiple logistic regression
analysis to determine which were independently related
to the end-points. All statistical comparisons were two-
tailed, and a value of p  < 0.05 was considered as
significant.
The predictive accuracy of the multivariate model was
evaluated using the C statistic, an index that reflects the
area under the receiver operating characteristic curve.
The odds ratio (OR) values obtained in the multivariate
analysis were used to develop the scoring system in theBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/8
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following way: if the OR was between 1 and 1.9, one point
was adjudicated; two points if it was between 2 and 2.9;
three points between 3 and 3.9 and four points if it
exceeded the last value.
Once the risk score was developed we conducted a valida-
tion phase to assess its prognostic accuracy in a prospec-
tively collected new sample of patients. Finally, we
applied the score to the entire population (from the deri-
vation and validation sets) to assess its value in a larger
group of patients with unstable angina.
The overall predictive ability of the risk score was then
assessed with the C statistic and compared with that
obtained from the multivariate model of the development
phase.
Results
Score development phase
Four hundred and seventy three patients were prospec-
tively included in this phase. Mean follow-up was 8.5 ±
9.3 days. Demographic and baseline characteristics are
shown in Table 1. Mean age of the population was 63.5 ±
11.8 years. Almost 60 % of patients had some kind of ECG
changes at admission; T waves changes and ST segment
deviation showed a similar prevalence. Troponin-T test
was positive in almost one fourth of the patients and half
of them had a C-reactive protein value greater than 3 mg/
L.
Table 2 shows the results of the univariate analysis. Age ≥
70 years, previous coronary artery bypass surgery, previ-
ous aspirin and nitrates treatment, ST segment deviation
and a positive troponin test at admission were predictors
of the predefined composite end-point. C-reactive protein
did not turn out to be a significant predictor of outcome,
neither using a cut-off point ≥ 3 mg/L nor another ≥ 10
mg/L.
Age was a statistically significant factor either used as a
continuous (C statistic: 0.65) or as a categorical variable
(C statistic: 0.64). The best cut-off point using the receiver
Table 1: Baseline characteristics
Development phase [n:473] Validation phase [n:242]
n%n%
Age [mean ± SD] 63.5 ± 11.8 63.7 ± 11.2
Age ≥ 70 y 159 33.6 80 33.1
Male sex 316 66.8 167 69.0
Recent onset angina 298 63.0 150 62.0
Progressive angina 175 37.0 92 38.0
Hypertension 325 68.7 155 64.0
Diabetes 88 18.6 49 20.2
Hypercholesterolemia 272 57.5 142 58.7
Current smokers 196 41.4 114 47.1
Previous MI 144 30.4 72 29.9
Previous PCI 61 12.9 34 14.0
Previous CABG 60 12.7 25 10.3
Medication before admission
Aspirin 286 60.5 146 60.3
Beta-blockers 202 42.7 119 49.2
Nitrates 102 21.6 67 27.7
Calcium antagonists 127 26.8 64 26.4
ACE-inhibitors 129 27.3 71 29.3
ECG changes
ST deviation 144 30.4 73 30.2
T wave inversion 137 29.0 60 24.8
No changes 192 40.6 109 45.0
Biochemical markers
Positive troponin test 99 20.9 53 21.9
CRP ≥ 3 mg/L 240 50.7 156 64.4
CRP ≥ 10 mg/L 149 31.5 81 33.5
ACE = angiotensin converting enzyme; CABG = coronary artery bypass grafting; CRP = C-reactive protein; MI = myocardial infarction; PCI = 
percutaneous coronary interventionBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/8
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operating curve was 70 years. Thus, age ≥ 70 years was
chosen for inclusion in the multivariate analysis.
So, 10 variables were included in the multivariate analysis
and only ST segment deviation, age, previous coronary
artery bypass surgery and a positive troponin test
remained as independent predictors (Table 3). The C sta-
tistic for the multivariable model was 0.76 (95% CI: 0,70–
0,83).
Therefore, according to the OR obtained, the scoring sys-
tem was established as follows: ST deviation (OR = 4.03):
4 points; age ≥ 70 years (OR = 2.29): 2 points; previous
bypass surgery (OR = 2.21): 2 points, and positive tro-
ponin test (OR = 2): 2 points. As the highest possible score
was 10 points, we divided it in tertiles so that we could
assign each patient to one of three categories according to
the score sum value: low-risk when it was 0 or 2, interme-
diate-risk when it was 4 or 6 and high-risk when it was 8
or 10.
Fourteen patients (3 %) died, 20 (4.2 %) had an AMI and
33 (7 %) developed refractory angina during in-hospital
evolution. The incidence of the triple end-point was 12.3
% and the corresponding figure for the double end-point
was 6.6 %.
Validation phase
Two hundred and forty two patients entered this phase of
the study. Baseline characteristics were similar to the first
Table 2: Results of the univariate analysis
Variable Composite end-point χ2 pO R 9 5 % C I
Present (%) Absent (%)
Age (mean ± SD) 68.8 ± 11.3 62.7 ± 11.6 0.0002
Age ≥ 70 y 56.9 30.4 16.06 0.00006 3.03 1.66 – 5.53
Male sex 60.3 67.7 1.25 0.26 0.73 0.40 – 1.33
Hypertension 67.2 68.9 0.07 0.79 0.93 0.40 – 1.75
Diabetes 20.7 18.3 0.19 0.66 1.16 0.55 – 2.42
Smokers 29.3 43.1 3.46 0.06 0.55 0.29 – 1.04
Hypercholesterolemia 62.1 56.9 0.56 0.45 1.24 0.68 – 2.28
Previous MI 39.7 29.2 2.65 0.10 1.60 0.87 – 2.93
Previous PCI 13.8 12.8 0.05 0.82 1.09 0.45 – 2.58
Previous CABG 25.9 10.8 10.36 0.001 2.87 1.39 – 5.87
Medication before admission
Aspirin 75.9 58.5 6.46 0.011 2.23 1.14 – 4.45
Beta-blockers 50.0 41.8 1.40 0.23 1.39 0.77 – 2.52
Nitrates 32.8 20.0 4.85 0.02 1.94 1.02 – 3.7
ACE-inhibitors 25.9 27.5 0.07 0.78 0.92 0.46 – 1.79
ECG changes
T wave inversion 13.8 31.1 7.39 0.006 0.35 0.15–0.81
ST deviation 63.8 25.5 34.97 0.000001 5.1 2.74 – 9.55
Biochemical markers
Positive troponin test 41.4 21.0 11.81 0.0005 2.66 1.43 – 4.93
C R P ≥ 3 mg/L 61.7 58.0 0.29 0.58 1.34 0.75 – 2.39
C R P ≥ 10 mg/L 41.7 31.1 2.72 0.09 1.56 0.86 – 2.83
ACE = angiotensin converting enzyme; CABG = coronary artery bypass grafting; CRP = C-reactive protein; MI = myocardial infarction; PCI = 
percutaneous coronary intervention; χ2 = chi-square.
Table 3: Results of the multivariate analysis.
Variable β coefficient OR 95% CI p Score Points
ST segment deviation 1,394 4.03 2.21 – 7.36 0.0001 4
Age ≥ 70 y 0,831 2.29 1.26 – 4.16 0.006 2
Previous CABG 0,795 2.21 1.07 – 4.57 0.032 2
Positive troponin test 0,692 2.0 1.08 – 3.70 0.028 2BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/8
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cohort (Table 1) except for a slightly higher prevalence of
elevated C-reactive protein (>3 mg/L) in the validation
cohort. The incidence of the different end-points was also
similar to that observed in the first group: double end-
point 6.6 % and triple end-point 12.8 %. Fifteen patients
were classified as high risk (6.2 %), 74 as intermediate risk
(30.6 %) and 153 as low risk (63.2 %) (Figure 1).
Incidence of the different end-points according to risk cat-
egorization is described in Table 4. There was a signifi-
cantly higher incidence both of the triple and double end-
points for the high risk compared to the low risk group:
46.6 % vs. 8.5 % [OR 9.4, 95 % CI 2.5 to 35, p = 0.0004],
for the triple end-point, and 33.3 % vs. 3.3 % [OR 14.8,
95 % CI 3 to 74, p = 0.0005] for the double one. Similar
results were found between the high risk and intermediate
risk groups: 46.6 % vs. 16.2 % [OR 4.5, 95 % CI 1.2 to
17.4, p = 0.01] for the triple end-point, and 33.3 % vs. 8.1
% [OR 5.7, 95 % CI 1.2 to 27, p = 0.01] for the double
end-point. Differences between the intermediate and the
low risk groups showed a slight trend but did not achieve
statistical significance: 16.2 % vs. 8.5 % for the triple end-
point (p = 0.12) and 8.1 % vs. 3.3 % for the double one
(p = 0.18).
Risk stratification in the entire population
When the already validated scoring system was applied to
the entire population (development plus validation
phases; n = 715), striking differences were found among
the low, intermediate and high risk subsets. Low risk
patients comprised 62.8 % of the whole population (n =
449); intermediate risk, 30.6 % (n = 219) and high risk,
6.6 % (n = 47) (Figure 1). Coronary angiography was per-
Distribution of risk groups in the validation phase [green bars] and in the entire population [red bars] Figure 1
Distribution of risk groups in the validation phase [green bars] and in the entire population [red bars]. LR: low-risk; IR: inter-
mediate-risk; HR: high-risk.
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formed in 47.7 % of the population and revascularization
procedures in 27.8 %.
The triple end-point occurred in 6 % of low risk patients,
19.2 % of intermediate risk and 44.7 % of high risk
patients [OR for high vs. low risk: 12.6, 95 % CI 5.9 to
26.8, p < 0.001; OR for high vs. intermediate risk: 3.4, 95
% CI 1.6 to 6.9, p < 0.001; OR for intermediate vs. low
risk: 3.7, 95 % CI 2.1 to 6.4, p < 0.001].
Incidence of the double end-point was also significantly
different among the three risk groups: 2 % for low risk,
11.4 % for intermediate risk and 27.6 % for high risk
patients [OR for high vs. low risk: 18.7, 95 % CI 6.8 to
51.6, p < 0.001; OR for high vs. intermediate risk: 2.9, 95
% CI 1.3 to 6.7, p = 0.003; OR for intermediate vs. low
risk: 6.3, 95 % CI 2.7 to 14.8, p < 0.001] (Table 5 and Fig-
ure 2).
Predictive power of the score, as assessed by the C statistic,
was 0.72 (95% CI: 0.66–0.78), similar to that found for
the multivariate model.
Discussion
Although many clinical, electrocardiographic and bio-
chemical markers have been clearly shown to correlate
with short and long-term prognosis in UA, few efforts
have been made to group them in order to improve their
individual predictive power.
The scoring system proposed here is quite simple to
obtain and has a good ability to discriminate risk accord-
ing to the C-statistic value. All the information needed is
available at admission or just a few hours after the last epi-
sode of pain, it is non-expensive and, what is most impor-
tant, it has a very good prognostic value. We divided the
population studied into three groups: low, intermediate
and high-risk, which is a common practice among cardi-
ologists regarding this or other diseases. The probability
of developing serious events, not only refractory angina
but also acute myocardial infarction or death, is enhanced
about ten times from the low to the high risk group.
The TIMI group has reported an interesting proposal of a
risk score for UA and non-ST elevation myocardial infarc-
tion [13]. They found a significant relationship between
the score ranging from 0 to 7 points and outcome. How-
ever, some important limitations to this study must be
pointed out. It was based on a population derived from
trials of therapeutic interventions which had stringent
inclusion and exclusion criteria preventing the applica-
tion of the results to a general population of this kind of
patients. Serum cardiac markers were not well defined, so
that different markers were used in different patients.
Finally, the inclusion of an angiographic variable may not
be practical as many patients with UA do not have a pre-
vious coronary angiography performed. Therefore,
although it seems difficult to make a direct comparison
between the TIMI risk score and ours, we think that our
proposal may have a similar accuracy to predict risk in the
whole population with UA and may be simpler to obtain
at admission in the clinical practice. The smaller size of
our cohort implies that these results should be repro-
duced in a larger one in order to make definite compari-
sons with other scoring systems.
A recently published study coming from Spain, the PEPA
registry, deserves some comments. The authors performed
a multicenter registry with 4115 unselected patients with
suspected non-ST-segment elevation acute coronary syn-
Table 4: Outcomes according to risk categorization in the validation phase.
End-point Low-risk [n = 153] Intermediate-risk [n = 74] High-risk [n = 15]
Triple 8.5 % 16.2 % * 46.6 % §†
Double 3.3 % 8.1 % # 33.3 % ** †
* p = 0.12 vs LR, §p = 0.0004 vs LR, † p = 0.01 vs IR, # p = 0.18 vs LR, ** p = 0.0005 vs LR
Table 5: Outcomes according to risk categorization in the entire population
End-point Low risk n = 449 Intermediate risk n = 219 High risk n = 47
Triple 6.0 % 19,2 % * 44,7 % * §
Double 2,0 % 11,4 % * 27,6 % * †
* p < 0.00001 vs LR, §p = 0.0003 vs IR, † p = 0.003 vs IRBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/8
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dromes. They found that age, diabetes, peripheral vascular
disease, postinfarction angina, Killip class, ECG and car-
diac markers were independent predictors of death. They
also developed a risk score based on such variables that
showed an interesting predictive power. Ninety days mor-
tality ranged from 0.4 % when no risk factor was present
to 21 % for patients with more than 4 risk factors [15].
Since our study is not an interventional trial, inclusion
biases are avoided. We did not include postinfarction
angina and non-ST elevation myocardial infarctions since
biochemical markers (troponins and C-reactive protein)
would not be useful in these entities as they should always
be elevated in patients with recent myocardial necrosis
because of their high sensitivity. Therefore, results apply
only to patients with a clinical diagnosis of UA. We must
remark that the traditional definition of AMI was used in
this study. If the new definition proposed by the ESC /
ACC Committee had been used, some patients would be
categorized as having an evolving AMI at admission, since
21 % of them had an elevated troponin level [16].
We chose a qualitative analysis of troponin T because it
can be performed bedside, it is not expensive and is
widely available in coronary care units from our country
and elsewhere [17]. The cut-off value of 0.1 ng/mL has
been validated as an useful predictor of major events in
UA [7,18], including a recently published large trial which
showed that a positive test doubles the risk of death or
AMI [20]. Both troponin T and troponin I have been con-
sistently shown to be powerful prognostic variables in
patients with UA [20–23]. As a rather high cut-off level
was selected for our trial, it is possible that some "not-low
risk" patients were not detected.
Incidence of end-points according to risk groups in the entire population Figure 2
Incidence of end-points according to risk groups in the entire population. Triple end-point [green bars] and double end-point 
[red bars]. LR: low-risk; IR: intermediate-risk; HR: high-risk.
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C-reactive protein had, in our experience, no predictive
value for in-hospital events. This is in agreement with sev-
eral reports, but may be related to the cut-off values we
chose. In fact, there is no agreement about which should
be the best cut-off point for C-reactive protein values in
order to use it in a risk score. However, although this
marker does not seem to be a good short-term prognostic
variable, it could be useful for the long-term outcome
[7,24–26]. Although the kind of assay (immunoturbidi-
metric) performed in this study has been extensively used,
it is possible that with newer techniques (high-sensitivity
assay) results could be somewhat different.
The finding of ST segment changes as the strongest predic-
tor of outcome was not surprising since ECG is widely
accepted as a useful prognostic factor beyond any doubt
[4,27].
The high prevalence of patients categorized as low-risk is
noteworthy. This figure reflects the non-selected popula-
tion included in this study. Many low risk patients are
excluded from trials of therapeutic interventions as they
generally have very stringent entry criteria. We believe our
sample is representative of the "real world" patients
admitted in our country to coronary care units with UA.
The overall outcome of our patients is quite similar to that
reported in the OASIS Registry for the short-term follow-
up, which included 7987 patients from six different coun-
tries, 87 % with UA as admission diagnosis [28]. The very
low incidence of serious events (refractory ischemia, inf-
arction or death) seen in the low risk group confirms the
risk category in which they were included based on our
score.
In the same way, the quite high C statistic reported here
may be explained by the non selected population with
higher prognostic value of different variables as it has
been shown regarding troponin T as a prognostic factor in
cohort studies versus clinical trials [29].
On the other hand, there is a minority of patients classi-
fied as high-risk, but they actually have a very poor out-
come. The intermediate-risk group is almost in the middle
of the other two when in-hospital events are considered.
Maybe some factors not included in the score should be
used in this particular subset in order to define their prog-
nosis more precisely. We cannot rule out the possibility
that the relatively small sample size could have limited
the number of variables that showed statistical signifi-
cance in the multivariate analysis performed.
Our findings should be tested in a larger cohort of patients
in order to suggest clinical strategies based on them. If
these data were confirmed, a highly aggressive approach
should be recommended in high-risk patients and a more
conservative one could be reserved for the low-risk group,
as has been recently suggested by Solomon et al. [30]
working on the TIMI IIIB study population. Patients cate-
gorized as low or very low risk, which comprised more
than half of the population, did not show any benefit
from an invasive treatment strategy, as did patients cate-
gorized as high or very high risk.
Conclusions
The syndrome of UA comprises highly different patients
and, consequently, a wide spectrum of clinical outcomes.
There is general agreement that a risk stratification strategy
is necessary in order to provide the best treatment to each
patient. We developed a simple scoring system, easy to
obtain at any institution, which showed a good capability
to separate patients with UA into low, intermediate and
high risk groups. The score proposed here was entirely
developed and validated in a prospective fashion, on
patients admitted to coronary care units without inclusion
biases. Further prospective studies with larger populations
are needed to confirm the practical use of this scoring
system.
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